Paul Plante
Internal Medicine · Columbia, SCNPI 1508825464
Payments from drug & device makers
Across 505 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$969
- Boehringer Ingelheim$458
- Amgen$456
- Pfizer$398
- Novartis$394
- plus $4K from 45 others
What the payments were for
- Consulting fees$220%
- Food & beverage$7,80399%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,900 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 117 | $172,693 |
| AustedoDeutetrabenazine | 12 | $102,265 |
| FarxigaDapagliflozin Propanediol | 73 | $86,169 |
| JardianceEmpagliflozin | 42 | $55,449 |
| EliquisApixaban | 55 | $50,989 |
| Repatha SureclickEvolocumab | 37 | $33,843 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $30,432 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $27,114 |
| TrulicityDulaglutide | 17 | $26,778 |
| MyrbetriqMirabegron | 35 | $26,704 |
| Repatha SyringeEvolocumab | 23 | $22,602 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $22,578 |
| EntrestoSacubitril/Valsartan | 23 | $21,444 |
| XareltoRivaroxaban | 15 | $18,782 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $17,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $286 | $172,693117 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,029 | $116,602118 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $126 | $102,26512 claims |
| Boehringer IngelheimJardiance, Glyxambi | $458 | $62,58954 claims |
| PfizerEliquis, Premarin | $398 | $59,30971 claims |
| Lilly USA, LLCTrulicity, Humalog | $383 | $32,12732 claims |
| Astellas Pharma US IncMyrbetriq | $246 | $26,70435 claims |
| NovartisEntresto | $394 | $21,44423 claims |
| Johnson & JohnsonXarelto | $221 | $18,78215 claims |
| GSKTrelegy Ellipta | $225 | $11,56013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $302 | $9,40814 claims |
| AbbVieSynthroid | $969 | $3,12037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Columbia
- Carl MitchellColumbia$564K
- Ronald CassadaColumbia$100K
- Meer FakhryColumbia$22K
- Charles ButlerColumbia$19K
- Laura LabooneColumbia$16K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.